|
G |
Acan |
aggrecan |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Actb |
actin, beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA |
CTD |
PMID:15477007 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein] |
CTD |
PMID:19217379 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adm |
adrenomedullin |
decreases expression multiple interactions |
EXP ISO |
Ionomycin results in decreased expression of ADM mRNA [Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein Ionomycin results in decreased expression of ADM mRNA; Ionomycin results in decreased expression of ADM protein |
CTD |
PMID:11470465 PMID:20682585 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AHR mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and affects the localization of AHR protein |
CTD |
PMID:9415701 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PX-866 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; STO 609 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; W 7 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22317921 PMID:28634229 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA Ionomycin results in increased expression of ATF4 protein |
CTD |
PMID:15477007 PMID:32578922 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] |
CTD |
PMID:18439569 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Bach2 |
BTB domain and CNC homolog 2 |
increases expression |
ISO |
Ionomycin results in increased expression of BACH2 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr 5:46,632,338...46,982,676
Ensembl chr 5:46,638,317...46,977,877
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
C5ar1 |
complement C5a receptor 1 |
increases expression |
ISO |
Ionomycin results in increased expression of C5AR1 protein |
CTD |
PMID:18559098 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases expression |
EXP ISO |
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] Ionomycin results in increased expression of CALCA protein [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein] Ionomycin results in increased expression of CALCA mRNA |
CTD |
PMID:2470235 PMID:12574409 PMID:20682585 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calr |
calreticulin |
decreases response to substance multiple interactions |
ISO |
CALR protein results in decreased susceptibility to Ionomycin Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA] |
CTD |
PMID:7961812 PMID:32220932 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]] |
CTD |
PMID:19217379 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
ISO |
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein |
CTD |
PMID:33392831 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
multiple interactions |
ISO |
CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28634229 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; Calcium deficiency inhibits the reaction [Ionomycin results in increased activity of CASP3 protein] |
CTD |
PMID:12165276 PMID:29803841 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP8 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:12165276 PMID:15477007 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL11 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL2 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA] |
CTD |
PMID:15477007 PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL5 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG protein |
CTD |
PMID:22851303 |
|
NCBI chr X:135,127,119...135,138,302
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Ionomycin results in increased expression of CD55 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd69 |
Cd69 molecule |
increases expression multiple interactions |
ISO |
Ionomycin results in increased expression of CD69 mRNA 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein |
CTD |
PMID:23134680 PMID:24247028 PMID:26343699 PMID:30171972 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein |
CTD |
PMID:31958493 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
decreases expression multiple interactions |
ISO |
Ionomycin results in decreased expression of CD86 protein [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein |
CTD |
PMID:23376802 PMID:31958493 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdh17 |
cadherin 17 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein] |
CTD |
PMID:19217379 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cfl1 |
cofilin 1 |
multiple interactions |
ISO |
Egtazic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein]; Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein |
CTD |
PMID:17303079 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
EXP |
Ionomycin results in increased activity of CFTR protein |
CTD |
PMID:15389550 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein; Auranofin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein] |
CTD |
PMID:10820281 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cln3 |
CLN3 lysosomal/endosomal transmembrane protein, battenin |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:181,156,071...181,169,458
Ensembl chr 1:181,156,073...181,167,434
|
|
G |
Cln8 |
CLN8, transmembrane ER and ERGIC protein |
multiple interactions |
ISO |
CLN8 protein affects the reaction [[Ionomycin co-treated with Calcium] results in increased transport of D-Aspartic Acid] |
CTD |
PMID:22302580 |
|
NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA |
CTD |
PMID:15477007 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSF2 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
multiple interactions |
ISO |
Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Cul5 |
cullin 5 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 protein |
CTD |
PMID:9415701 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Ionomycin results in increased expression of DDIT3 protein |
CTD |
PMID:32578922 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA] |
CTD |
PMID:10652249 |
|
NCBI chr15:96,025,729...96,065,114
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein] |
CTD |
PMID:23775084 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DPYD mRNA |
CTD |
PMID:15705907 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions increases phosphorylation |
EXP |
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin results in increased phosphorylation of DRD3 protein] |
CTD |
PMID:19217379 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Ionomycin results in increased abundance of Calcium] which results in increased expression of EGR1 protein |
CTD |
PMID:12517959 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
increases expression |
ISO |
Ionomycin results in increased expression of EVI2A mRNA |
CTD |
PMID:24247028 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG protein; Tamoxifen inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA] |
CTD |
PMID:20529085 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Ionomycin results in increased expression of FOS mRNA] |
CTD |
PMID:9580328 PMID:9650640 PMID:15477007 PMID:15705907 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fyb1 |
FYN binding protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:55,621,585...55,781,206
Ensembl chr 2:55,632,698...55,779,629
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA |
CTD |
PMID:22398747 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion |
ISO |
Ionomycin results in increased secretion of GH1 protein |
CTD |
PMID:12471042 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein] |
CTD |
PMID:19217379 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein |
CTD |
PMID:30171972 |
|
NCBI chr15:30,343,361...30,346,792
Ensembl chr15:30,173,603...30,346,814
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion multiple interactions |
ISO EXP |
Ionomycin results in increased secretion of HEXB protein Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; KN 93 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; ML 7 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [Ionomycin results in increased secretion of HEXB protein] |
CTD |
PMID:14499669 PMID:19758318 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity |
ISO |
Curcumin analog inhibits the reaction [Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]]; Curcumin analog inhibits the reaction [Ionomycin results in increased activity of HIF1A protein]; Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein] |
CTD |
PMID:20554536 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression |
EXP |
Ionomycin results in increased expression of HK2 mRNA |
CTD |
PMID:17516843 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
ISO |
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]] |
CTD |
PMID:19277450 |
|
NCBI chr17:10,368,355...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 protein] |
CTD |
PMID:10652249 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; Estradiol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Resveratrol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA] 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [2,4-diaminotoluene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Azathioprine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein]; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] |
CTD |
PMID:12411406 PMID:12812920 PMID:15358692 PMID:15379866 PMID:15588918 PMID:16154495 PMID:16716911 PMID:17475810 PMID:17572062 PMID:17685462 PMID:19277450 PMID:21569788 PMID:22077062 PMID:22398747 PMID:26343699 PMID:29594315 PMID:30171972 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr2 |
interferon gamma receptor 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr11:30,779,733...30,798,005
Ensembl chr11:30,779,733...30,798,005
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; catechol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; hydroxyhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; quinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein] [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Genistein affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein] |
CTD |
PMID:12884291 PMID:15588918 PMID:16716911 PMID:17572062 PMID:17685462 PMID:19277450 PMID:22398747 PMID:29777833 More...
|
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA; biochanin A promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; daidzein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; formononetin promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Genistein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; hexaconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; T0901317 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; tetraconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; triflumizol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] [Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein |
CTD |
PMID:22289359 PMID:25583575 PMID:27783946 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL1B protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein] |
CTD |
PMID:17572062 PMID:17685462 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
multiple interactions increases expression |
ISO EXP |
[Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [bis(tri-n-butyltin)oxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Sodium Dodecyl Sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA] Ionomycin results in increased expression of IL2 mRNA 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; 4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dexamethasone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Formaldehyde co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [isophorone diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mitomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pyrimethamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [sodium bromate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; NECAME_02783 protein modified form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Zinc Sulfate inhibits the reaction [Ionomycin results in increased expression of IL2 mRNA] |
CTD |
PMID:8658534 PMID:8662742 PMID:9439728 PMID:11592964 PMID:12165276 PMID:12411406 PMID:12812920 PMID:15379866 PMID:15477007 PMID:15588918 PMID:16055081 PMID:16154495 PMID:16241859 PMID:16531003 PMID:17572062 PMID:17615583 PMID:17630204 PMID:17685462 PMID:18423386 PMID:19277450 PMID:19880376 PMID:21075198 PMID:21569788 PMID:22398747 PMID:23134680 PMID:26343699 PMID:29594315 PMID:29777833 PMID:34051231 More...
|
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21 |
interleukin 21 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein] |
CTD |
PMID:22077062 |
|
NCBI chr 2:120,119,598...120,126,941
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions increases secretion |
ISO EXP |
[Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2RA protein 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] |
CTD |
PMID:8586487 PMID:9766631 PMID:22398747 PMID:23134680 PMID:26343699 PMID:30171972 More...
|
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein] |
CTD |
PMID:10820229 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein] [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; [Toluene 2,4-Diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]] |
CTD |
PMID:8658534 PMID:9766631 PMID:10820229 PMID:12709020 PMID:12884291 PMID:15588918 PMID:17572062 PMID:17685462 PMID:19277450 PMID:22398747 PMID:29777833 PMID:31958493 More...
|
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO EXP |
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein] deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein] |
CTD |
PMID:8658534 PMID:12884291 PMID:17475810 PMID:17572062 PMID:17685462 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein] Ionomycin results in increased expression of IL6 mRNA |
CTD |
PMID:10820229 PMID:12884291 PMID:17572062 PMID:17685462 PMID:18434080 PMID:20682585 PMID:22398747 PMID:29777833 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il9 |
interleukin 9 |
increases expression multiple interactions |
ISO |
Ionomycin results in increased expression of IL9 mRNA [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein] |
CTD |
PMID:10820229 |
|
NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,111,772...8,114,895
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiopental inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] |
CTD |
PMID:9580328 PMID:15263067 PMID:15477007 PMID:15705907 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnn3 |
potassium calcium-activated channel subfamily N member 3 |
multiple interactions increases activity |
EXP |
[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium] |
CTD |
PMID:15634793 |
|
NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein; Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein] |
CTD |
PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]] |
CTD |
PMID:17615583 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] |
CTD |
PMID:15263067 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
increases expression |
ISO |
Ionomycin results in increased expression of LAMP1 protein |
CTD |
PMID:23376802 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Ltbp4 |
latent transforming growth factor beta binding protein 4 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:82,600,136...82,634,346
Ensembl chr 1:82,600,136...82,632,178
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] |
CTD |
PMID:12574409 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:15477007 PMID:16877402 PMID:18423386 PMID:19217379 PMID:22317921 PMID:23134680 PMID:23775084 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] Ionomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:15477007 PMID:16877402 PMID:18423386 PMID:22317921 PMID:23134680 PMID:23775084 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases phosphorylation multiple interactions |
ISO EXP |
Ionomycin results in decreased phosphorylation of MAPT protein Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein] |
CTD |
PMID:9200503 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
EXP |
Ionomycin results in increased phosphorylation of MYL9 protein Trifluoperazine inhibits the reaction [Ionomycin results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:19233221 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Naa80 |
N(alpha)-acetyltransferase 80, NatH catalytic subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
increases response to substance |
EXP |
NCS1 protein results in increased susceptibility to Ionomycin |
CTD |
PMID:12471042 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions decreases phosphorylation |
ISO |
Hydrogen Peroxide inhibits the reaction [Ionomycin results in decreased phosphorylation of NFATC1 protein] |
CTD |
PMID:12203019 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions |
ISO |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein; Acetic Acid inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of and results in decreased phosphorylation of NFATC2 protein; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein] |
CTD |
PMID:17615583 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
multiple interactions affects localization |
ISO EXP |
[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] Ionomycin affects the localization of NFATC3 protein |
CTD |
PMID:12709020 PMID:15799720 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases localization |
EXP |
Ionomycin results in increased localization of NFATC4 protein |
CTD |
PMID:16849427 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases response to substance decreases response to substance multiple interactions |
ISO |
NFE2L2 gene mutant form results in increased susceptibility to Ionomycin NFE2L2 protein results in decreased susceptibility to Ionomycin [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NFE2L2 protein |
CTD |
PMID:12842875 PMID:24632381 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein] |
CTD |
PMID:15477007 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nmi |
N-myc (and STAT) interactor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Notch3 |
notch receptor 3 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28634229 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions |
EXP |
PLCB1 protein promotes the reaction [Ionomycin results in increased abundance of Inositol Phosphates] |
CTD |
PMID:11377826 |
|
NCBI chr 3:122,059,968...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18423386 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Ionomycin results in increased expression of PMAIP1 mRNA |
CTD |
PMID:24247028 |
|
NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pnpla4 |
patatin like phospholipase domain containing 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr X:42,313,554...42,318,451
Ensembl chr X:42,305,373...42,318,552
|
|
G |
Pou2f1 |
POU class 2 homeobox 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of POU2F1 protein |
CTD |
PMID:16241859 |
|
NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363
|
|
G |
Pou2f2 |
POU class 2 homeobox 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:80,682,330...80,769,756
Ensembl chr 1:80,685,741...80,724,261
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
EXP |
Cyclosporine inhibits the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]; KN 62 affects the reaction [Ionomycin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:17516843 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23775084 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
multiple interactions |
ISO |
PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23775084 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein |
CTD |
PMID:30171972 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkcq |
protein kinase C, theta |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein] |
CTD |
PMID:16241859 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22398747 |
|
NCBI chr19:33,830,958...33,833,442
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Psmb8 |
proteasome 20S subunit beta 8 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22398747 |
|
NCBI chr20:4,652,159...4,655,122
Ensembl chr20:4,652,159...4,655,283
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
Ionomycin results in increased phosphorylation of and results in increased activity of PTK2B protein |
CTD |
PMID:16877402 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of RBPJ protein |
CTD |
PMID:23134680 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
increases expression |
ISO |
Ionomycin results in increased expression of RCAN1 protein |
CTD |
PMID:12927602 |
|
NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rhog |
ras homolog family member G |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257
|
|
G |
Rnaset2 |
ribonuclease T2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:52,576,344...52,603,151
Ensembl chr 1:52,585,929...52,603,147
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RT1-DA protein |
CTD |
PMID:9536116 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sart1 |
spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:202,690,472...202,699,136
Ensembl chr 1:202,690,459...202,699,136
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Ionomycin results in increased expression of SERPINE1 mRNA |
CTD |
PMID:15961275 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sf3b4 |
splicing factor 3B subunit 4 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 2:183,732,791...183,737,545
Ensembl chr 2:183,732,754...183,737,959
|
|
G |
Sftpb |
surfactant protein B |
increases secretion |
ISO EXP |
Ionomycin results in increased secretion of SFTPB protein |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion |
ISO EXP |
Ionomycin results in increased secretion of SFTPC protein |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
EXP |
Ionomycin results in increased expression of SIRT1 protein |
CTD |
PMID:17581637 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
|
|
G |
Slc39a7 |
solute carrier family 39 member 7 |
multiple interactions |
ISO |
Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] |
CTD |
PMID:22317921 |
|
NCBI chr20:4,823,166...4,826,538
Ensembl chr20:4,822,012...4,826,537
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
SOD2 protein results in decreased susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] |
CTD |
PMID:22429591 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA] |
CTD |
PMID:32220932 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Srpra |
SRP receptor subunit alpha |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470
|
|
G |
Stim1 |
stromal interaction molecule 1 |
multiple interactions |
ISO |
[Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] |
CTD |
PMID:18439569 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Syn1 |
synapsin I |
affects response to substance |
ISO |
SYN1 protein affects the susceptibility to Ionomycin |
CTD |
PMID:22759588 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA] |
CTD |
PMID:22398747 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
EXP |
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TFRC protein |
CTD |
PMID:9766631 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFB1 mRNA |
CTD |
PMID:18434080 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Ionomycin inhibits the reaction [[N-(4-hydroxyphenyl)arachidonylamide co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; NECAME_02783 protein modified form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] |
CTD |
PMID:10820229 PMID:10890505 PMID:12411406 PMID:15358692 PMID:16154495 PMID:17196940 PMID:17572062 PMID:17685462 PMID:18434080 PMID:19277450 PMID:21075198 PMID:22398747 PMID:29777833 PMID:31958493 PMID:34051231 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:15477007 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfrsf4 |
TNF receptor superfamily member 4 |
multiple interactions increases expression |
EXP |
Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]] |
CTD |
PMID:9766631 |
|
NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
multiple interactions |
ISO |
[Ionomycin co-treated with Phorbol Esters] promotes the reaction [entinostat results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [trichostatin A results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [vorinostat results in increased expression of TNFSF9 mRNA] |
CTD |
PMID:19759901 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnpo1 |
transportin 1 |
increases expression |
ISO |
Ionomycin results in increased expression of TNPO1 mRNA |
CTD |
PMID:10843682 |
|
NCBI chr 2:30,207,529...30,300,162
Ensembl chr 2:30,211,510...30,300,375
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
multiple interactions increases activity |
ISO |
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein Ionomycin results in increased activity of TRPM4 protein |
CTD |
PMID:25047048 PMID:33392831 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO EXP |
Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]] Ionomycin results in increased activity of TRPV1 protein |
CTD |
PMID:11606325 PMID:19553475 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity |
EXP |
Ionomycin results in increased activity of TRPV3 protein |
CTD |
PMID:21726418 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases activity |
EXP |
Ionomycin results in increased activity of TRPV4 protein |
CTD |
PMID:21726418 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
Ionomycin results in decreased expression of TXNIP mRNA |
CTD |
PMID:10843682 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA] |
CTD |
PMID:15477007 |
|
NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA |
CTD |
PMID:15477007 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [deoxynivalenol results in decreased expression of ZEB1 protein] |
CTD |
PMID:11893416 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|